Investigating how certain mutations in protein kinase A contribute to rare tumors
Official title: Targeting Oncogenic PKA signaling mechanisms
Funded at University of California, San Francisco · NIH-11001594 · Data updated 2026-11-12
This study is looking at how certain gene changes cause rare tumors in the endocrine system and liver, and it aims to find new treatments that can better help patients with these specific cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | December 15, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $588,909 |
| NIH project number | 5R01CA279997-02 |
| Project ID | NIH-11001594 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with rare endocrine or hepatic tumors driven by oncogenic mutations in protein kinase A.
✕Less likely to help
Patients with common cancers or tumors not associated with protein kinase A mutations may not benefit from this research.
What this research studies
This research focuses on understanding the molecular mechanisms behind rare endocrine and hepatic tumors caused by mutations in protein kinase A (PKA). By examining how these mutations lead to abnormal cell signaling, the team aims to identify new therapeutic strategies that specifically target the downstream effects of these mutations. The approach involves profiling oncogenic PKAc mutants and exploring their impact on mRNA translation, which is crucial for tumor growth. This could lead to the development of targeted treatments that are more effective for patients with these rare cancers.
Why it matters
Potential benefit: If successful, this research could lead to new, effective therapies for patients suffering from rare tumors that currently lack established treatments.
How similar studies have gone: Previous research has shown promise in targeting oncogenic mutations in protein kinases, suggesting that this approach could lead to significant advancements in treatment for rare cancers.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Gordan, John D — University of California, San Francisco
- Study coordinator: Gordan, John D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.